Rodica Pop-Busui, MD, PhD, Larry D. Soderquist Professor, is a Professor in the Department of Internal Medicine in the Division of Metabolism, Endocrinology & Diabetes (MEND), Co-Director of the Michigan Peripheral Neuropathy Center, and Vice Chair of Clinical Research at the University of Michigan.
Dr. Pop-Busui is a nationally and internationally recognized leader in the field of diabetes as a result of her extensive clinical, research, teaching, and service activities. She has received awards from the Fulbright Foundation, the American Diabetes Association, and the University of Michigan. Since 2013, Dr. Pop-Busui has been an elected member of the Clinical Practice Committee of the American Diabetes Association (ADA), the world’s leading organization dedicated to preventing and curing diabetes. Dr. Pop-Busui also served as a member of the Complications Study Section of the Juvenile Diabetes Research Foundation (JDRF), a member of the study section of the American Heart Association, and a member of the National Institutes of Health NIH ZDK1 GRB-J J3 and NIH ZDK1GRB-S (O2) Study Sections.
Due to Dr. Pop-Busui's scholarship efforts, she is internationally recognized as an expert in the field of diabetes complications, especially diabetic neuropathies. A particular focus of her research interest and efforts involve diabetic peripheral and cardiovascular autonomic neuropathy. She has received funding for her research from the National Heart, Lung, and Blood Institute (NHLBI), the National Institute of Diabetes and Digestive & Kidney Diseases (NIDDK), the JDRF and the ADA. In addition, Dr. Pop-Busui has been privileged to contribute her research efforts to some of the most important national diabetes clinical studies to date, which have advanced the understanding of diabetes, informed changes in its treatment, and impacted the standard of care, thereby improving the lives of people affected by diabetes
As an investigator and site Principal Investigator of the NHLBI-funded Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, Dr. Pop-Busui leads a team of ACCORD investigators from the United States and Canada in exploring the role of cardiac autonomic neuropathy on cardiovascular mortality in the study participants, and the effects of interventions on neuropathy risks in this cohort. As an investigator of the NIDDK-funded Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), Dr. Pop-Busui took the lead in studies evaluating the natural history and the impact of metabolic memory on cardiovascular autonomic neuropathy in this cohort, and the role of cardiovascular autonomic neuropathy in the development of left ventricular dysfunction in type 1 diabetes.
Most recently, Dr. Pop-Busui is the site Principal Investigator and member of the Steering Committee of the newly funded NIDDK trial "PERL: A Multicenter Clinical Trial of Allopurinol to Prevent GFR Loss in Type 1 Diabetes" and site Principal Investigator in the NIDDK-funded trial "Glycemia Reduction Approaches for Diabetes: A Comparative Effectiveness Study (GRADE)." Â In addition, as a member of the American Diabetes Association Clinical Practice Committee, Dr. Pop-Busui has made major contributions to the Standards of Clinical Care in Diabetes in 2013 and 2014, and advocated for implementing the optimal care for diabetes and its complications, based on most rigorous scientific evidence, with the ultimate goal to improve the life of all people affected by diabetes.
Dr. Pop-Busui has devoted her life and career to the treatment and understanding of diabetes and its devastating complications, a commitment forged when she was a medical school resident and saw in her rotations the suffering of people with diabetes. Dr. Pop-Busui lives in Ann Arbor with her husband.